This article is more than 5 years old. Information may no longer be current.
IOP-lowering solution launches under Westminster Pharmaceuticals
Click Here to Manage Email Alerts
Trxade Group Inc. and its subsidiary, Westminster Pharmaceuticals LLC, have launched brimonidine solution 0.2% as part of an exclusive agreement with Indoco Remedies Ltd., according to a press release from the company.
The solution is designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension patients.
The treatment generated sales of approximately $6.8 million for year-end Dec. 31, 2014, according to IMS Health data.
Remedies will manufacture and supply Westminster with all dosage strengths, according to the press release. Westminster will market and distribute the product under its own private label in the U.S. and begin its initial distribution during the current quarter.
Under the terms of the agreement, Indoco will receive a share of the net profits from Westminster's sales of the product.
The agreement runs until the end of 2022.